viewAntibe Therapeutics Inc

Antibe Therapeutics hosts successful annual and special general meeting

The firm said shareholders elected six directors at its annual general meeting

Antibe's lead drug, ATB-346, targets acute and chronic pain associated with osteoarthritis and its Phase 2B dose-ranging efficacy study for the drug remains on track

Antibe Therapeutics (CVE:ATE) (OTCMKTS:ATBPF) released a shareholder update Tuesday, which highlighted its annual general and special meeting, noting all resolutions outlined in the management information circular were approved. 

The firm noted shareholders elected a number of directors: Roderick Flower, Amal Khouri, Daniel Legault, Walt Macnee, John Wallace and Yung Wu. 

Shareholders also approved the reappointment of Ernst & Young LLP, Chartered Accountants, as Antibe's auditor, as well as an amendment to the restricted share unit plan. 

READ: Antibe Therapeutics updates on Phase 2 progress of lead drug ATB-346

Antibe's lead drug, ATB-346, targets acute and chronic pain associated with osteoarthritis and its Phase 2B dose-ranging, efficacy study for the drug remains on track.

The firm is developing a platform of unique drugs to prevent gastrointestinal damage and bleeding caused by using non-steroidal anti-inflammatory drugs known as NSAIDs, which are currently the primary therapy for pain relief. 

Shares of Antibe were at C$0.32 on Tuesday. 

Contact Katie Lewis at [email protected]

Quick facts: Antibe Therapeutics Inc

Price: 0.69 CAD

Market: TSX-V
Market Cap: $194.09 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company...



Full interview: Antibe Therapeutics finishes Phase 2 trial for ATB-346;...

Antibe Therapeutics (CVE: ATE OTCQB: ATBPF) CEO Dan Legault joined Steve Darling from Proactive Vancouver to share details about how the company is dealing with the Pandemic crisis and if they are seeing any effect on their Phase 2 study with their lead drug, ATB-346. Legault also told Proactive...

on 7/4/20

2 min read